Biotech with Phase 3 Rheumatoid Arthritis and Psoriasis Trials Raises Capital, Now 'Funded Through Catalysts'
Source: Streetwise Reports  (7/8/20)
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report. More >

Preclinical COVID-19 Vaccine Data 'Encouraging'
Source: Streetwise Reports  (7/8/20)
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report. More >

Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial
Source: Streetwise Reports  (7/8/20)
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications. More >

Analyst: G1 Minimizes the Carnage of Chemotherapy
Source: Streetwise Reports  (7/1/20)
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. More >

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug
Source: Streetwise Reports  (7/1/20)
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. More >

Life Sciences Firm Submits IND Application to FDA for Phase 3 COVID-19 Study
Source: Streetwise Reports  (7/1/20)
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2. More >

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study
Source: Streetwise Reports  (7/1/20)
Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. More >

Biopharma's Multinational COVID-19 Study Receives US Ethics Approval
Source: Streetwise Reports  (6/30/20)
Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well. More >

Vaxart Shares Rise 95% After Signing Agreement for Oral Tablet COVID-19 Vaccine
Source: Streetwise Reports  (6/25/20)
Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually. More >

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity
Source: Streetwise Reports  (6/24/20)
These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. More >

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines
Source: Streetwise Reports  (6/23/20)
Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas. More >

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients
Source: Streetwise Reports  (6/19/20)
Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. More >

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie
Source: Streetwise Reports  (6/18/20)
Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. More >

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment
Source: Streetwise Reports  (6/17/20)
The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. More >

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results
Source: Streetwise Reports  (6/16/20)
Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. More >

Life Sciences Firm Expands Collaboration Efforts with Major U.S. University to Develop Psilocybin-Based Medicines
Source: Streetwise Reports  (6/15/20)
Revive Therapeutics Ltd. reported it has expanded its research partnership for novel formulation development and clinical research of psilocybin with the University of Wisconsin-Madison. More >

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study
Source: Streetwise Reports  (6/15/20)
Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. More >

Reata Pharma Announces $350 Million Strategic Investment from Blackstone Life Sciences
Source: Streetwise Reports  (6/11/20)
Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases. More >

Life Sciences Firm Pursues Phase 3 COVID-19 Treatment Trial in Canada
Source: Streetwise Reports  (6/10/20)
Revive Therapeutics met with Health Canada to discuss how best to proceed. More >

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody
Source: Streetwise Reports  (6/10/20)
Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. More >

Enochian Shares Trade Up 50% upon Concluding FDA Meeting for Potential HIV Cure
Source: Streetwise Reports  (6/8/20)
Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV. More >

FDA Greenlights Biopharma for Trial of Possible COVID-19 Therapeutic
Source: Streetwise Reports  (6/4/20)
Algernon Pharmaceuticals prepares to commence the Phase 2b study as soon as possible. More >

Micro-Cap Pharma Moving Ahead with Plans for Phase 3 US Trial of a Repurposed Drug for Covid-19
Source: Streetwise Reports  (6/3/20)
Revive Therapeutics is focused on infectious diseases as well as treatments using psilocybin-based formulations. More >

Immunotherapy Firm Releases Data Showing Treatment Potential Against Sepsis
Source: Streetwise Reports  (6/3/20)
Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report. More >

Cassava Shares Rise on Updated Phase 2b Alzheimer's Drug Trial Data
Source: Streetwise Reports  (6/3/20)
Shares of Cassava Sciences traded 70% higher after the firm provided updates from its Phase 2b study of PTI-125 for use in treating Alzheimer' disease. More >